Name: MIRUM PHARMACEUTICALS INC (MIRM) Stock
Brand: MIRUM PHARMACEUTICALS INC
Rating: 6 (3 reviews)

MIRM Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Chartmill

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup

18 hours ago - By: Zacks Investment Research - Mentions: XENE

Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?

2 days ago - By: The Motley Fool

Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026

3 days ago - By: The Motley Fool - Mentions: AUPH TARS GLPG PTCT

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?

3 days ago - By: Zacks Investment Research - Mentions: CRMD ADMA ARQT

MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study

4 days ago - By: Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

10 days ago - By: Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

24 days ago - By: Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®

a month ago - By: Zacks Investment Research - Mentions: ANIP NTLA ARQT

MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened

a month ago - By: Benzinga

What Analysts Are Saying About Mirum Pharmaceuticals Stock

a month ago - By: Zacks Investment Research - Mentions: GLUE

Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates

a month ago - By: Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Benzinga - Mentions: KURA SEE HRMY FOLD ...

Earnings Scheduled For November 4, 2025

a month ago - By: Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

a month ago - By: Zacks Investment Research - Mentions: TECH

Techne (TECH) Reports Next Week: What to Know Ahead of the Release

a month ago - By: Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

2 months ago - By: Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

3 months ago - By: Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

4 months ago - By: Yahoo Finance - Mentions: MS CMI HSBC LINE ...

Arm initiated, Adobe downgraded: Wall Street's top analyst calls

4 months ago - By: Zacks Investment Research - Mentions: TCRX

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: Mirum Pharmaceuticals, Inc.

MIRUM PHARMACEUTICALS INC (MIRM) Stock News

MIRM Latest News, Press Relases and Analysis

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup

Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue?

Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?

MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study

Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®

MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened

What Analysts Are Saying About Mirum Pharmaceuticals Stock

Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates

Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Earnings Scheduled For November 4, 2025

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Techne (TECH) Reports Next Week: What to Know Ahead of the Release

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Arm initiated, Adobe downgraded: Wall Street's top analyst calls

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update